SCHEMBL4451312

SCHEMBL4451312

COC(=O)c1ccc(CNS(=O)(=O)c2cccc(CCN)c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.63
MAPT P10636 8/20 0.52
ALDH1A1 P00352 4/20 0.51
GAA P10253 2/20 0.51
RECQL P46063 1/20 0.51
LMNA P02545 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 2/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HTR6 P50406 1/20 0.49
CYP19A1 P11511 1/20 0.49
LOXL2 Q9Y4K0 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HSD11B1 P28845 1/20 0.48
NAMPT P43490 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4451522 0.91 LOXL2 (0.54) POLBMAPTLMNASMN1; SMN2HPGD
SCHEMBL3850206 0.81 POLB (0.72) POLBMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL119461 0.79 POLB (0.72) POLBMAPTALDH1A1GAALMNA
SCHEMBL20981410 0.77 ALDH1A1 (0.68) POLBMAPTALDH1A1GAALMNA
SCHEMBL14049770 0.77 AKR1C3 (0.52) POLBMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL13628247 0.76 NAMPT (0.55) POLBMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL3012713 0.75 LOXL2 (0.76) MAPTALDH1A1SMN1; SMN2HPGDLOXL2
SCHEMBL230590 0.75 LOXL2 (0.72) MAPTALDH1A1HPGDLOXL2MEN1
Hydrochloric Acid SCHEMBL4447485 0.74 LOXL2 (0.73) MAPTALDH1A1SMN1; SMN2HPGDLOXL2
SCHEMBL1287354 0.74 POLB (0.65) POLBMAPTALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275583-A1 ANTIVIRAL COMPOUNDS AND USE THEREOF MYRIAD GENETICS, INCORPORATED (US) 2009-11-05 US disclosed
WO-2008127364-A2 ANTIVIRAL COMPOUNDS AND USE THEREOF MYRIAD GENETICS, INC. (US) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275583-A1 ANTIVIRAL COMPOUNDS AND USE THEREOF MAVS, ZC3HAV1, EIF2AK2 POLB 117/4885MAPT 2949/4885ALDH1A1 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.